<div id="readability-page-1"><p>Mediar Therapeutics, Inc. announced that it has received $76 million in an oversubscribed round of funding co-led by new investors Amplitude Ventures Inc. and ICG America, Inc. on January 7, 2026. The company has received $38,150,185 in it's final tranche. The transaction included participation from new investors Longwood Fund, Asahi Kasei Pharma America Corporation and Alexandria Real Estate Equities, Inc. The transaction also included participation from existing investors Bristol-Myers Squibb Company, Eli Lilly and Company, Gimv NV, Mass General Brigham Ventures, LLC, Mission BioCapital, LP, Novartis Venture Funds, Ono Venture Investment, Inc., Pfizer Venture Investments LLC, Pureos Partners AG and Sofinnova Partners SAS.</p></div>

旭化成(ADR)

辉瑞

百时美施贵宝

AMPL

<p>Mediar Therapeutics, Inc. 宣布于 2026 年 1 月 7 日获得了来自一组投资者的 7600 万美元融资，该轮融资由 Amplitude Ventures Inc.和 ICG America, Inc.共同主导。此次融资轮超额认购，最后一笔融资金额为 38,150,185 美元。新投资者包括 Longwood Fund 和旭化成制药美国公司，而现有投资者如百时美施贵宝和辉瑞也参与了此次融资</p>

Mediar Therapeutics, Inc. announced that it has received $76 million in funding from a group of investors

- Mediar Therapeutics, Inc. 收到 7600 万美元融资，由新投资者共同牵头。  
- 各参与方包括 Amplitude Ventures Inc. 和 ICG America, Inc.。  
- 此次交易中也有众多现有投资者参与。

Mediar Therapeutics, Inc.宣布已获得来自一组投资者的 7600 万美元融资